Amylin Analogs and Obesity: Cagrilintide and the Combination with Semaglutide

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Cagrilintide, an amylin analog, combined with semaglutide offers a synergistic approach to weight loss by targeting both satiety and gastric emptying.

While GLP-1 receptor agonists have transformed obesity management, the pursuit of even greater efficacy has led to the exploration of co-agonists and novel mechanisms. Amylin analogs, particularly cagrilintide, in combination with semaglutide, represent a significant advancement in this area, leveraging complementary pathways to achieve superior weight loss.

Understanding Amylin's Role in Satiety and Metabolism

Amylin, also known as islet amyloid polypeptide (IAPP), is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta-cells in response to nutrient intake. Its physiological roles include slowing gastric emptying, suppressing post-prandial glucagon secretion, and promoting satiety via central nervous system mechanisms [1]. By enhancing feelings of fullness and reducing food intake, amylin contributes to glucose homeostasis and body weight regulation.

In individuals with obesity, amylin signaling can be dysregulated, contributing to increased appetite and weight gain. Therefore, targeting the amylin pathway presents a rational therapeutic strategy for obesity.

Cagrilintide: A Potent Amylin Analog

Cagrilintide is a long-acting amylin analog designed to mimic and enhance the effects of native amylin. Its extended half-life allows for once-weekly administration, improving patient convenience and adherence. As a monotherapy, cagrilintide has demonstrated significant weight loss in clinical trials by effectively reducing appetite and food intake [2].

CagriSema: The Synergistic Combination with Semaglutide

The true potential of cagrilintide has been realized in its combination with semaglutide, a potent GLP-1 receptor agonist, forming the co-formulation known as CagriSema. This dual-agonist approach capitalizes on the distinct yet complementary mechanisms of action of both peptides:

Semaglutide (GLP-1 RA): Primarily acts by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central mechanisms.

Cagrilintide (Amylin Analog): Further slows gastric emptying, promotes satiety, and potentially modulates energy expenditure through distinct pathways from GLP-1.

The synergy between these two agents leads to more profound and sustained weight loss than either drug alone. The REDEFINE clinical trial program has provided compelling evidence for CagriSema's efficacy:

REDEFINE 1 (Adults with overweight/obesity without diabetes): In a 68-week phase 3 study, participants receiving once-weekly CagriSema achieved an average body weight reduction of 20.4%, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3% with placebo. When accounting for full treatment adherence, weight loss with CagriSema reached 22.7%, with 40.4% of participants achieving at least 25% weight loss [3].

REDEFINE 2 (Adults with overweight/obesity and type 2 diabetes): In this 68-week phase 3 trial, CagriSema led to an average weight loss of 13.7% compared to 3.4% with placebo. For participants adhering to treatment, weight loss increased to 15.7% [3]. Additionally, 73.5% of patients in the CagriSema group achieved a glycated hemoglobin (HbA1c) level of 6.5% or less, compared to 15.9% in the placebo group, highlighting its significant glycemic benefits [2].

Clinical Implications and Safety Profile

The substantial weight loss achieved with CagriSema positions it as a highly effective therapeutic option, approaching the efficacy observed with bariatric surgery. Beyond weight reduction, CagriSema has also demonstrated improvements in cardiometabolic risk factors, including reductions in waist circumference and systolic blood pressure [3].

The safety profile of CagriSema is generally consistent with the GLP-1 receptor agonist class, with gastrointestinal adverse events (e.g., nausea, vomiting, diarrhea, constipation) being the most common. These events are typically mild to moderate in severity and transient, often manageable with dose titration. Discontinuation rates due to adverse events, while slightly higher with CagriSema compared to monotherapies or placebo, remain low [2, 3].

Conclusion

Cagrilintide, particularly in combination with semaglutide as CagriSema, represents a powerful new frontier in obesity pharmacotherapy. By synergistically targeting both GLP-1 and amylin pathways, it offers enhanced weight loss and metabolic improvements, providing a valuable tool for clinicians in the comprehensive management of obesity and its associated comorbidities.

References

[1] De Silva, A., & Bloom, S. R. (2012). Gut Hormones and Appetite Control: A Focus on PYY and GLP-1. Gut and Liver, 6(1), 10–20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3286726/

[2] Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., ... & Pedersen, S. D. (2025). Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 393(7), 648-659. https://www.nejm.org/doi/10.1056/NEJMoa2502082

[3] American Diabetes Association. (2025, June 22). CagriSema Demonstrates Significant Weight Loss in Adults with Obesity. Press Release. https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity